Tresiba

Tresiba is a brand-name long-acting insulin analog, the active ingredient being insulin degludec. It is used to improve glycemic control in adults with type 1 or type 2 diabetes, and in some pediatric patients, when used as a basal component of insulin therapy. Tresiba is typically given once daily, at a time that fits the patient’s routine, with dose individualized to achieve target blood glucose levels.

Degludec forms soluble multi-hexamers after subcutaneous injection, which gradually release insulin monomers. This produces a flat, peakless action profile with a duration of action reported up to about 42 hours, allowing sustained basal coverage and reducing pronounced peaks compared with some other basal insulins.

Tresiba is available in U-100 and U-200 concentrations in prefilled pens (FlexTouch). It is administered by subcutaneous injection and is not intended for intravenous use. Dosing is determined by a healthcare professional and may be used as the basal insulin in type 1 diabetes (often in combination with rapid-acting mealtime insulin) or as monotherapy or in combination with other antidiabetic agents in type 2 diabetes.

Common adverse effects include hypoglycemia, weight gain, and injection-site reactions. Lipodystrophy can occur with repeated injections at the same site. The risk of hypoglycemia increases with dose changes, missed meals, or increased exercise. Rare allergic reactions and immune-mediated effects can occur. Gender, pregnancy, and lactation considerations should be discussed with a clinician, as insulin use requires individualized medical supervision.

Storage: unopened vials or pens should be refrigerated until first use. After first use, Tresiba pens can be stored at room temperature away from heat and light for a period specified in the product labeling; always follow the current labeling for exact storage durations.